Arjuna Natural Pvt. Ltd

arjunanatural.com

Arjuna_Natural_Pvt
Established in 1990, and through more than three decades of stead and continuous growth, Arjuna Natural extracts Ltd; is today India's leading company specializing in scientific methods of identification, separation and manufacturing of plant based active compounds.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

MISSION BIO ANNOUNCES PHARMA ASSAY DEVELOPMENT SERVICES FOR SOLID TUMOR RESEARCH

Mission Bio | July 18, 2022

news image

Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced the launch of solid tumor assays through its Pharma Assay Development (PAD) services. The availability of this new service offering will help to accelerate the development of cancer therapeutics by reducing the time and cost associated with the characterization of solid tumor cells. Precision therapeutics for solid tumors have been historically bottlenecked due to technical challe...

Read More

Industrial Impact, Medical

SENSIBLE BIOTECHNOLOGIES ANNOUNCES PARTNERSHIP WITH GINKGO BIOWORKS TO DEVELOP NOVEL MRNA MANUFACTURING PLATFORM

prnewswire | April 04, 2023

news image

Sensible Biotechnologies, an early stage biotechnology company, today announced a partnership to develop an in vivo microbial mRNA manufacturing platform with Ginkgo Bioworks which is building the leading platform for cell programming and biosecurity. Today, the vast majority of mRNA used in vaccines, therapeutics and other applications is produced by in vitro transcription (IVT), a cell-free process, which is driven by purified enzymes. In conventional mRNA manufacturing, produ...

Read More

Cell and Gene Therapy

ILLUMINA UNVEILS REVOLUTIONARY NOVASEQ X SERIES TO RAPIDLY ACCELERATE GENOMIC DISCOVERIES AND IMPROVE HUMAN HEALTH

Illumina, Inc | September 30, 2022

news image

Illumina, Inc. a global leader in DNA sequencing and array-based technologies, announced the launch of the NovaSeq™ X Series new production-scale sequencers that will push the limits of what is possible with genomic medicine, enabling faster, more powerful, and more sustainable sequencing. Using revolutionary new technology, NovaSeq X Plus can generate more than 20,000 whole genomes per year – 2.5 times the throughput of prior sequencers – greatly accelerating genomic discovery...

Read More

Cell and Gene Therapy, Industrial Impact

OXFORD NANOPORE TECHNOLOGIES COLLABORATES WITH UPS HEALTHCARE

Oxford Nanopore Technologies | February 17, 2023

news image

On February 16, 2023, Oxford Nanopore Technologies announced that it will be furthering its collaboration with UPS Healthcare to expedite the distribution of its Oxford Nanopore DNA/RNA sequencing products and consumables throughout the Asia Pacific region. The collaborative effort will strengthen the supply chain for Oxford Nanopore's portable, real-time DNA sequencing devices in key markets across Asia. By leveraging the specialized healthcare logistics solutions provided ...

Read More
news image

Cell and Gene Therapy

MISSION BIO ANNOUNCES PHARMA ASSAY DEVELOPMENT SERVICES FOR SOLID TUMOR RESEARCH

Mission Bio | July 18, 2022

Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced the launch of solid tumor assays through its Pharma Assay Development (PAD) services. The availability of this new service offering will help to accelerate the development of cancer therapeutics by reducing the time and cost associated with the characterization of solid tumor cells. Precision therapeutics for solid tumors have been historically bottlenecked due to technical challe...

Read More
news image

Industrial Impact, Medical

SENSIBLE BIOTECHNOLOGIES ANNOUNCES PARTNERSHIP WITH GINKGO BIOWORKS TO DEVELOP NOVEL MRNA MANUFACTURING PLATFORM

prnewswire | April 04, 2023

Sensible Biotechnologies, an early stage biotechnology company, today announced a partnership to develop an in vivo microbial mRNA manufacturing platform with Ginkgo Bioworks which is building the leading platform for cell programming and biosecurity. Today, the vast majority of mRNA used in vaccines, therapeutics and other applications is produced by in vitro transcription (IVT), a cell-free process, which is driven by purified enzymes. In conventional mRNA manufacturing, produ...

Read More
news image

Cell and Gene Therapy

ILLUMINA UNVEILS REVOLUTIONARY NOVASEQ X SERIES TO RAPIDLY ACCELERATE GENOMIC DISCOVERIES AND IMPROVE HUMAN HEALTH

Illumina, Inc | September 30, 2022

Illumina, Inc. a global leader in DNA sequencing and array-based technologies, announced the launch of the NovaSeq™ X Series new production-scale sequencers that will push the limits of what is possible with genomic medicine, enabling faster, more powerful, and more sustainable sequencing. Using revolutionary new technology, NovaSeq X Plus can generate more than 20,000 whole genomes per year – 2.5 times the throughput of prior sequencers – greatly accelerating genomic discovery...

Read More
news image

Cell and Gene Therapy, Industrial Impact

OXFORD NANOPORE TECHNOLOGIES COLLABORATES WITH UPS HEALTHCARE

Oxford Nanopore Technologies | February 17, 2023

On February 16, 2023, Oxford Nanopore Technologies announced that it will be furthering its collaboration with UPS Healthcare to expedite the distribution of its Oxford Nanopore DNA/RNA sequencing products and consumables throughout the Asia Pacific region. The collaborative effort will strengthen the supply chain for Oxford Nanopore's portable, real-time DNA sequencing devices in key markets across Asia. By leveraging the specialized healthcare logistics solutions provided ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us